B-Luc-EGFP SU-DHL-1_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

Please input keywords

Order

*Country

日本

アメリカ

中国

オーストラリア

シンガポール

イギリス

フランス

ドイツ

スイス

イタリア

カナダ

韓国

オランダ

ベルギー

スウェーデン

その他

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

B-Luc-EGFP SU-DHL-1

Common name	B-Luc-EGFP SU-DHL-1	Catalog number	322063
Aliases	NA	Disease	Large cell lymphoma;ddiffuse histiocytic lymphoma
Organism	Human	Strain	NA
Tissue types	Lymphoma	Tissue	Lymphoma

Description

This B-Luc-EGFP SU-DHL-1 cell line expresses firefly luciferase as a marker of SU-DHL-1 cells. Fluorescence and EGFP could be detected in B-Luc-EGFP SU-DHL-1 cells.

Application

B-Luc-EGFP SU-DHL-1 cell line can be used to evaluate anti-cancer drugs in large cell lymphoma or ddiffuse histiocytic lymphoma in vivo.

Targeting strategy

Gene targeting strategy for B-Luc-EGFP SU-DHL-1 cells. The CMV promoter and luciferase-EGFP were inserted into the targeting vector used in the lentivirus system.

In vitro luciferase activity of B-Luc-EGFP SU-DHL-1 cells

from clipboard

Luminescence signal intensity of B-Luc-EGFP SU-DHL-1 cells. Luminescence intensity was measured using the Bright-GloTM luciferase Assay (Promega, Cat E2610). B-Luc-EGFP SU-DHL-1 cells have a strong luminescence signal. EGFP was detected in B-Luc-EGFP SU-DHL-1 cells. The 1-D10 clone of B-Luc-EGFP SU-DHL-1 cells can be used in vivo experiments.

Quantitative imaging data & body weight changes

from clipboard

B-Luc-EGFP SU-DHL-1 cells (5x10⁶) were injected into the tail vein of wild-type B-NDG mice. Signal intensity and body weight were measured twice a week. (A) Imaging was performed twice a week. (B) Body weight (Mean ± SEM). B-Luc-EGFP SU-DHL-1 cells can be used for in vivo efficacy evaluation.